Volume Alert - ARNA 4.55 Arena Pharmaceuticals $AR
Post# of 71
Posted On: 11/12/2014 1:47:22 PM
Volume Alert - ARNA 4.55 Arena Pharmaceuticals $ARNA Hit a high today of 4.58 Closing the day 10:29 at 4.55 +0.06 +1.34% With a day low of 4.44 and a total volume of 1,323,012.
ARNA Recent Posts: http://investorshangout.com/Arena-Pharmaceuti...RNA-53369/
ARNA Arena Pharmaceuticals Recent Headline News
Bel-Phen Pilot Study News, Hold On To Your Shares
Rx Stocks - at Seeking Alpha - Tue Nov 11, 12:13PM CST
OREX: 5.95 (+0.91), VVUS: 3.26 (-0.01), ARNA: 4.70 (+0.21)
Can Arena Pharmaceuticals Inc. Overcome Belviq's Slow Launch?
George Budwell, The Motley Fool - Motley Fool - Tue Nov 11, 10:15AM CST
The new generation of diet pills approved by the Food and Drug Administration have stumbled out of the gate. Specifically, Arena Pharmaceuticals ' Belviq and VIVUS 's Qsymia reported a combined 283,000 prescriptions in the third quarter, with...
PFE: 30.49 (+0.17), VVUS: 3.26 (-0.01), GSK: 45.52 (-0.44), ARNA: 4.70 (+0.21)
Why Orexigen Therapeutics, Inc. Stock Skyrocketed
Sean Williams, The Motley Fool - Motley Fool - Mon Nov 10, 5:52PM CST
Although we don't believe in timing the market or panicking over market movements, we do like to keep an eye on big changes -- just in case they're material to our investing thesis. What: Shares of Orexigen Therapeutics , a...
OREX: 5.95 (+0.91), VVUS: 3.26 (-0.01), ARNA: 4.70 (+0.21)
Arena And Vivus Investors Need To Watch Orexigen
Spencer Osborne - at Seeking Alpha - Mon Nov 10, 12:24PM CST
OREX: 5.95 (+0.91), VVUS: 3.26 (-0.01), ARNA: 4.70 (+0.21)
Orexigen rises as weight loss drug review proceeds
AP - Mon Nov 10, 10:02AM CST
NEW YORK (AP) — Shares of Orexigen Therapeutics Inc. jumped Monday after the company said a European Union review of its weight loss drug Contrave, which was approved in the U.S. in September, is progressing on schedule.
OREX: 5.95 (+0.91), VVUS: 3.26 (-0.01), ARNA: 4.70 (+0.21)
Belviq Sales Dip Slightly - Quarter Is Flat Thus Far
Spencer Osborne - at Seeking Alpha - Fri Nov 07, 12:02PM CST
VVUS: 3.26 (-0.01), ARNA: 4.70 (+0.21)
Vivus Beats The Street On Milestone Payment For ED Drug
Spencer Osborne - at Seeking Alpha - Thu Nov 06, 7:59AM CST
OREX: 5.95 (+0.91), VVUS: 3.26 (-0.01), ARNA: 4.70 (+0.21)
Will Belviq Advertising Pick Up Again?
Spencer Osborne - at Seeking Alpha - Thu Nov 06, 7:55AM CST
VVUS: 3.26 (-0.01), ARNA: 4.70 (+0.21)
Lorcaserin HCl Data to be Presented at the Annual Meeting of the American Association for the Study of Liver Diseases
PR Newswire - Thu Nov 06, 7:00AM CST
Eisai Inc. and Arena Pharmaceuticals, Inc. (NASDAQ: ARNA) announced today that data from the Phase 3 clinical trial program for lorcaserin HCl will be presented at the Annual Meeting of the American Association for the Study of Liver Diseases, also known as The Liver Meeting®, taking place November 7-11, 2014, in Boston, Massachusetts.
ARNA: 4.70 (+0.21)
Arena Pharmaceuticals to Present at Credit Suisse 2014 Healthcare Conference
PR Newswire - Wed Nov 05, 7:00AM CST
Arena Pharmaceuticals, Inc. (NASDAQ: ARNA) announced today that the company is scheduled to present a corporate overview and update at the Credit Suisse 2014 Healthcare Conference on Wednesday, November 12, 2014, at 3:00 p.m. Mountain Time (5:00 p.m. Eastern Time), at The Arizona Biltmore in Phoenix, Arizona.
ARNA: 4.70 (+0.21)
Arena Pharmaceuticals Posts In Line Q3 Loss, Belviq Grows - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Nov 04, 8:30AM CST
Arena Pharmaceuticals (ARNA) reported a net loss of 13 cents per share in the third quarter of 2014 in line with the Zacks Consensus Estimate.
VVUS: 3.26 (-0.01), AMAG: 35.00 (+0.12), ARNA: 4.70 (+0.21)
Orexigen's Contrave Has Modest Start
Spencer Osborne - at Seeking Alpha - Mon Nov 03, 12:30PM CST
OREX: 5.95 (+0.91), ARNA: 4.70 (+0.21)
Arena Beats The Street On Taigen Stock Sale
Spencer Osborne - at Seeking Alpha - Mon Nov 03, 12:26PM CST
ARNA: 4.70 (+0.21)
Arena Pharmaceuticals' (ARNA) CEO Jack Lief on Q3 2014 Results - Earnings Call Transcript
SA Transcripts - at Seeking Alpha - Mon Nov 03, 11:53AM CST
ARNA: 4.70 (+0.21)
Arena Pharmaceuticals (ARNA) Q3 2014 Results - Earnings Call Webcast
SA Transcripts - at Seeking Alpha - Mon Nov 03, 7:25AM CST
ARNA: 4.70 (+0.21)
Super Important Biotech and Drug Stock Events for November
at The Street - Mon Nov 03, 7:24AM CST
A cheat sheet of earnings, medical meetings, FDA approval decisions and clinical trial results for healthcare investors.
GILD: 107.13 (-0.88), CLVS: 58.15 (-3.16), ARWR: 6.53 (+0.03), ACHN: 14.27 (+1.79), MRK: 59.30 (-0.07), RTRX: 11.39 (+0.03), RGLS: 20.34 (-0.13), EPZM: 23.82 (-0.44), AGIO: 86.88 (+4.97), RMTI: 11.15 (unch), ARNA: 4.70 (+0.21), KERX: 15.46 (-0.48)
Arena product revenues up 185%
Seeking Alpha - at Seeking Alpha - Mon Nov 03, 6:36AM CST
ARNA: 4.70 (+0.21)
Arena Pharmaceuticals tops 3Q profit forecasts
Automated Insights - Mon Nov 03, 6:27AM CST
SAN DIEGO (AP) _ Arena Pharmaceuticals Inc. (ARNA) on Monday reported a third-quarter loss of $10.7 million.
ARNA: 4.70 (+0.21)
Arena Pharmaceuticals beats by $0.07, misses on revenue
Seeking Alpha - at Seeking Alpha - Mon Nov 03, 5:56AM CST
ARNA: 4.70 (+0.21)
Arena Pharmaceuticals Provides Corporate Update and Reports Third Quarter 2014 Financial Results
PR Newswire - Mon Nov 03, 5:45AM CST
Arena Pharmaceuticals, Inc. (NASDAQ: ARNA) today provided a corporate update and reported financial results for the third quarter ended September 30, 2014.
ARNA: 4.70 (+0.21)
ARNA Recent Posts: http://investorshangout.com/Arena-Pharmaceuti...RNA-53369/
ARNA Arena Pharmaceuticals Recent Headline News
Bel-Phen Pilot Study News, Hold On To Your Shares
Rx Stocks - at Seeking Alpha - Tue Nov 11, 12:13PM CST
OREX: 5.95 (+0.91), VVUS: 3.26 (-0.01), ARNA: 4.70 (+0.21)
Can Arena Pharmaceuticals Inc. Overcome Belviq's Slow Launch?
George Budwell, The Motley Fool - Motley Fool - Tue Nov 11, 10:15AM CST
The new generation of diet pills approved by the Food and Drug Administration have stumbled out of the gate. Specifically, Arena Pharmaceuticals ' Belviq and VIVUS 's Qsymia reported a combined 283,000 prescriptions in the third quarter, with...
PFE: 30.49 (+0.17), VVUS: 3.26 (-0.01), GSK: 45.52 (-0.44), ARNA: 4.70 (+0.21)
Why Orexigen Therapeutics, Inc. Stock Skyrocketed
Sean Williams, The Motley Fool - Motley Fool - Mon Nov 10, 5:52PM CST
Although we don't believe in timing the market or panicking over market movements, we do like to keep an eye on big changes -- just in case they're material to our investing thesis. What: Shares of Orexigen Therapeutics , a...
OREX: 5.95 (+0.91), VVUS: 3.26 (-0.01), ARNA: 4.70 (+0.21)
Arena And Vivus Investors Need To Watch Orexigen
Spencer Osborne - at Seeking Alpha - Mon Nov 10, 12:24PM CST
OREX: 5.95 (+0.91), VVUS: 3.26 (-0.01), ARNA: 4.70 (+0.21)
Orexigen rises as weight loss drug review proceeds
AP - Mon Nov 10, 10:02AM CST
NEW YORK (AP) — Shares of Orexigen Therapeutics Inc. jumped Monday after the company said a European Union review of its weight loss drug Contrave, which was approved in the U.S. in September, is progressing on schedule.
OREX: 5.95 (+0.91), VVUS: 3.26 (-0.01), ARNA: 4.70 (+0.21)
Belviq Sales Dip Slightly - Quarter Is Flat Thus Far
Spencer Osborne - at Seeking Alpha - Fri Nov 07, 12:02PM CST
VVUS: 3.26 (-0.01), ARNA: 4.70 (+0.21)
Vivus Beats The Street On Milestone Payment For ED Drug
Spencer Osborne - at Seeking Alpha - Thu Nov 06, 7:59AM CST
OREX: 5.95 (+0.91), VVUS: 3.26 (-0.01), ARNA: 4.70 (+0.21)
Will Belviq Advertising Pick Up Again?
Spencer Osborne - at Seeking Alpha - Thu Nov 06, 7:55AM CST
VVUS: 3.26 (-0.01), ARNA: 4.70 (+0.21)
Lorcaserin HCl Data to be Presented at the Annual Meeting of the American Association for the Study of Liver Diseases
PR Newswire - Thu Nov 06, 7:00AM CST
Eisai Inc. and Arena Pharmaceuticals, Inc. (NASDAQ: ARNA) announced today that data from the Phase 3 clinical trial program for lorcaserin HCl will be presented at the Annual Meeting of the American Association for the Study of Liver Diseases, also known as The Liver Meeting®, taking place November 7-11, 2014, in Boston, Massachusetts.
ARNA: 4.70 (+0.21)
Arena Pharmaceuticals to Present at Credit Suisse 2014 Healthcare Conference
PR Newswire - Wed Nov 05, 7:00AM CST
Arena Pharmaceuticals, Inc. (NASDAQ: ARNA) announced today that the company is scheduled to present a corporate overview and update at the Credit Suisse 2014 Healthcare Conference on Wednesday, November 12, 2014, at 3:00 p.m. Mountain Time (5:00 p.m. Eastern Time), at The Arizona Biltmore in Phoenix, Arizona.
ARNA: 4.70 (+0.21)
Arena Pharmaceuticals Posts In Line Q3 Loss, Belviq Grows - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Nov 04, 8:30AM CST
Arena Pharmaceuticals (ARNA) reported a net loss of 13 cents per share in the third quarter of 2014 in line with the Zacks Consensus Estimate.
VVUS: 3.26 (-0.01), AMAG: 35.00 (+0.12), ARNA: 4.70 (+0.21)
Orexigen's Contrave Has Modest Start
Spencer Osborne - at Seeking Alpha - Mon Nov 03, 12:30PM CST
OREX: 5.95 (+0.91), ARNA: 4.70 (+0.21)
Arena Beats The Street On Taigen Stock Sale
Spencer Osborne - at Seeking Alpha - Mon Nov 03, 12:26PM CST
ARNA: 4.70 (+0.21)
Arena Pharmaceuticals' (ARNA) CEO Jack Lief on Q3 2014 Results - Earnings Call Transcript
SA Transcripts - at Seeking Alpha - Mon Nov 03, 11:53AM CST
ARNA: 4.70 (+0.21)
Arena Pharmaceuticals (ARNA) Q3 2014 Results - Earnings Call Webcast
SA Transcripts - at Seeking Alpha - Mon Nov 03, 7:25AM CST
ARNA: 4.70 (+0.21)
Super Important Biotech and Drug Stock Events for November
at The Street - Mon Nov 03, 7:24AM CST
A cheat sheet of earnings, medical meetings, FDA approval decisions and clinical trial results for healthcare investors.
GILD: 107.13 (-0.88), CLVS: 58.15 (-3.16), ARWR: 6.53 (+0.03), ACHN: 14.27 (+1.79), MRK: 59.30 (-0.07), RTRX: 11.39 (+0.03), RGLS: 20.34 (-0.13), EPZM: 23.82 (-0.44), AGIO: 86.88 (+4.97), RMTI: 11.15 (unch), ARNA: 4.70 (+0.21), KERX: 15.46 (-0.48)
Arena product revenues up 185%
Seeking Alpha - at Seeking Alpha - Mon Nov 03, 6:36AM CST
ARNA: 4.70 (+0.21)
Arena Pharmaceuticals tops 3Q profit forecasts
Automated Insights - Mon Nov 03, 6:27AM CST
SAN DIEGO (AP) _ Arena Pharmaceuticals Inc. (ARNA) on Monday reported a third-quarter loss of $10.7 million.
ARNA: 4.70 (+0.21)
Arena Pharmaceuticals beats by $0.07, misses on revenue
Seeking Alpha - at Seeking Alpha - Mon Nov 03, 5:56AM CST
ARNA: 4.70 (+0.21)
Arena Pharmaceuticals Provides Corporate Update and Reports Third Quarter 2014 Financial Results
PR Newswire - Mon Nov 03, 5:45AM CST
Arena Pharmaceuticals, Inc. (NASDAQ: ARNA) today provided a corporate update and reported financial results for the third quarter ended September 30, 2014.
ARNA: 4.70 (+0.21)
(0)
(0)Arena Pharmaceuticals (ARNA) Stock Research Links
Scroll down for more posts ▼